The effect of corticotropin (ACTΗ-releasing hormone (CRH) administration on α-melanocyte-stimulating hormone (α-MSH), ACTH and β-endorphin (β-EPH) was evaluated in the inferior petrosal sinuses and in the periphery of 30 patients affected with Cushing’s disease subjected to simultaneous and bilateral inferior petrosal sinus sampling for diagnostic purposes. Baseline PRL levels, sensitivity to dexamethasone and surgery outcome were compared to α-MSH response. CRH bolus did not modify α-MSH concentrations either in the inferior petrosal sinuses or in the periphery in the 30 patients considered as a whole. In 7 of 30 patients, however, a greater than 50% increase over baseline α-MSH levels (from 50 to 115.5%) was recorded in the inferior petrosal sinus ipsilateral to the adenoma (from 42.9 ± 1.7 to 76.4 ± 4.6ng/l; p < 0.001), whereas no change was found in the contralateral inferior petrosal sinus or in the periphery. Conversely, as expected, ACTH and β-ELI significantly increased in all the patients after CRH both in the inferior petrosal sinuses and in the periphery (particularly in the inferior petrosal sinus ipsilateral to the adenoma). No difference in sensitivity to dexamethasone (urinary cortisol percent decrease: 66.4 ± 4.9 vs. 67.8 ± 3.4) and surgery outcome (χ2 test: p = 0.7) was found between patients with α-MSH response to CRH and patients without such a response. By contrast, baseline PRL levels, although being normal in both groups, were significantly higher in patients with α-MSH response to CRH (18.1 ± 1.6 vs. 10.1 ± 0.7 μg/l; p < 0.001). In conclusion, the results of the present study suggest that in a subset of patients with Cushing’s disease (23.3% of our series) α-MSH may be released after the administration of CRH together with ACTH and β-EPH by adenomatous corticotrophs. In this subset of patients, PRL levels may be in the upper normal range.

Keywords:
Corticotropin, β-Endorphin, α-Melanocyte-stimulating hormone, Inferior petrosal sinuses, Cushing’s disease, CRH test
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.